Pre-made Mepolizumab benchmark antibody ( Whole mAb, anti-IL5 therapeutic antibody, Anti-EDF/IL-5/TRF Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Mepolizumab biosimilar, Whole mAb, Anti-IL5 Antibody: Anti-EDF/IL-5/TRF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis, and hypereosinophilic syndrome (HES). It recognizes and blocks interleukin-5 (IL-5), a signalling protein of the immune system.
| Products Name (INN Index) | Pre-Made Mepolizumab biosimilar, Whole mAb, Anti-IL5 Antibody: Anti-EDF/IL-5/TRF therapeutic antibody |
|---|---|
| INN Name | Mepolizumab |
| Target | IL5 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 1999 |
| Year Recommended | 2000 |
| Companies | GlaxoSmithKline,McMaster University,National Institute of Allergy and Infectious Diseases |
| Conditions Approved | Asthma,Churg-Strauss syndrome,Hypereosinophilic syndrome |
| Conditions Active | Chronic obstructive pulmonary disease,Hypereosinophilic syndrome,Nasal polyps,Eosinophilic oesophagitis |
| Conditions Discontinued | Atopic dermatitis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL5 |
| Package |
